Cargando…

Inactivated SARS-CoV-2 vaccine for people with HIV

Detalles Bibliográficos
Autores principales:	Wolday, Dawit, de Wit, Tobias F. Rinke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8898081/ https://www.ncbi.nlm.nih.gov/pubmed/35265824 http://dx.doi.org/10.1016/j.eclinm.2022.101327

Ejemplares similares

Chronic Immune Activation and CD4(+) T Cell Lymphopenia in Healthy African Individuals: Perspectives for SARS-CoV-2 Vaccine Efficacy
por: Wolday, Dawit, et al.
Publicado: (2021)

HIV and SARS-CoV-2: the interplay of two wicked problems
por: Kiekens, Anneleen, et al.
Publicado: (2022)

Response to Abdelrahman M et al commentary on “Parasites Protect from Severe COVID-19. Myth or Reality?”
por: Wolday, Dawit, et al.
Publicado: (2022)

Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people living with HIV
por: Ao, Ling, et al.
Publicado: (2022)

Pregnant people deserve the protection offered by SARS-CoV-2 vaccines
por: Maykin, Melanie M., et al.
Publicado: (2021)

Increasing SARS-CoV-2 vaccination rates among Black people in Canada
por: Eissa, Azza, et al.
Publicado: (2021)

Prevention and Treatment of SARS-CoV2 Infection in People Living with HIV: The Need for Specific Data
por: Díaz, Natalia A., et al.
Publicado: (2021)

Guangdong’s Study of the Effectiveness of China’s Inactivated Vaccines Against the SARS-CoV-2 B.1.617.2 (Delta) Variant
por: Wang, Fuzhen, et al.
Publicado: (2021)

Inactivated SARS-CoV-2 vaccines elicit immunogenicity and T-cell responses in people living with HIV
por: Lv, Zhengchao, et al.
Publicado: (2022)

Inactivated vaccine for SARS-CoV-2
por: Risson, Emma
Publicado: (2020)

SARS-CoV-2 vaccination in people with HIV
por: Spinelli, Matthew A
Publicado: (2021)

Prognostic Value of C-Reactive Protein in SARS-CoV-2 Infection: A Simplified Biomarker of COVID-19 Severity in Northern Ethiopia
por: Gebrecherkos, Teklay, et al.
Publicado: (2023)

Timely development of vaccines against SARS-CoV-2
por: Lu, Shan
Publicado: (2020)

Is there a post-SARS-CoV-2 vaccination dementia?
por: Fiorini, Ana C., et al.
Publicado: (2022)

HLA Variation and SARS-CoV-2 Specific Antibody Response
por: Wolday, Dawit, et al.
Publicado: (2023)

Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people with gastrointestinal cancer
por: Li, Tong, et al.
Publicado: (2022)

Effectiveness of an Inactivated SARS-CoV-2 Vaccine
por: Wilder-Smith, Annelies, et al.
Publicado: (2021)

SARS-CoV-2 pandemic expanding in sub-Saharan Africa: Considerations for COVID-19 in people living with HIV
por: Drain, Paul K., et al.
Publicado: (2020)

Scaled testing for COVID-19 needs community involvement
por: Adams, Emily R, et al.
Publicado: (2021)

Unanticipated efficacy of SARS-CoV-2 vaccination in older adults
por: Pawelec, Graham, et al.
Publicado: (2021)

Multicomponent vaccines to fight SARS-CoV-2 variants of concern
por: Cassone, Antonio, et al.
Publicado: (2021)

The challenge of emerging SARS-CoV-2 mutants to vaccine development
por: Li, Rong, et al.
Publicado: (2021)

SARS-CoV-2 immunogenicity: Is S protein the best target for vaccination?
por: Antonopoulou, Tania, et al.
Publicado: (2022)

Questioning the justification for a fourth SARS-CoV-2 vaccine
por: Calderon-Margalit, Ronit, et al.
Publicado: (2022)

SARS-CoV-2 immunity and vaccine strategies in people with HIV
por: Mullender, Claire, et al.
Publicado: (2022)

Development of an inactivated vaccine candidate for SARS-CoV-2
por: Gao, Qiang, et al.
Publicado: (2020)

Development of an Inactivated Vaccine against SARS CoV-2
por: Pavel, Shaikh Terkis Islam, et al.
Publicado: (2021)

Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile
por: Jara, Alejandro, et al.
Publicado: (2021)

Immunogenicity of an inactivated SARS-CoV-2 vaccine in people living with HIV-1: a non-randomized cohort study
por: Feng, Yanmeng, et al.
Publicado: (2021)

SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for vaccines
por: Salvatori, Giovanni, et al.
Publicado: (2020)

Positive aspects of the mRNA platform for SARS-CoV-2 vaccines
por: Hajissa, Khalid, et al.
Publicado: (2021)

COVID-19 vaccines: Keeping pace with SARS-CoV-2 variants
por: Cevik, Muge, et al.
Publicado: (2021)

SARS-CoV-2 vaccination for immune-comprised patients: More is required
por: Li, Hui, et al.
Publicado: (2021)

T cells as the hoped-for savior for SARS-CoV-2 vaccination during CD20-depleting antibody therapy?: Commentary for: “Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy.”
por: Bsteh, Gabriel, et al.
Publicado: (2021)

Experimental studies using OMV in a new platform of SARS-CoV-2 vaccines
por: Gaspar, Emanuelle B., et al.
Publicado: (2021)

Immunological Analysis of People in Northeast China after SARS-CoV-2 Inactivated Vaccine Injection
por: Fu, Yu, et al.
Publicado: (2021)

Skin rashes after SARS‐CoV‐2 vaccine: which relationship, if any?
por: Patruno, Cataldo, et al.
Publicado: (2021)

Vaccine against SARS-CoV-2 in previously infected health care workers
por: Parisi, Saverio Giuseppe
Publicado: (2021)

Co-Occurrence of SARS-CoV-2 Infection and Inactivated SARS-CoV-2 Vaccination among Healthcare Workers
por: Cucunawangsih, Cucunawangsih, et al.
Publicado: (2021)

Pathogenicity of SARS‐CoV‐2 Omicron
por: Chu, Hin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_eeghlknm5u2tbstch2ncu9p8pr